



D. BORAL
— CAPITAL —

May 2025



Apimeds Pharmaceuticals
Treating today to improve tomorrow

\$13,500,000

Initial Public Offering
Sole Bookrunner



*For more information please
contact :*

Investment Banking

Gaurav Verma
Co-Head of Investment Banking
Direct: +1 (929) 528-0912
gverma@dboralcapital.com

Dr. David Sans
Senior Managing Director of
Healthcare Investment Banking
Direct: +1 (929) 528-0914
dsans@dboralcapital.com

Nolan Munafo
Investment Banking
Direct: +1 (929) 528-0905
nmunafo@dboralcapital.com

Equity Capital Markets

Philip Wiederlight
Chief Operating Officer
Direct: +1 (929) 625-1539
pwiederlight@dboralcapital.com

Mark Iorio
Director, Equity Capital Markets
Direct: +1 (929) 528-0913
miorio@dboralcapital.com

D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) in connection with its \$13.5 Million Initial Public Offering

Transaction Information

On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of \$4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.”

D. Boral Capital LLC (“D. Boral”) acted as sole bookrunner for the Offering.

About Apimeds Pharmaceuticals US, Inc.

Apimeds is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who fail to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

For more information visit www.apimedsus.com.

About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America.

A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately \$30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products.

D. Boral Capital is a member of FINRA and SIPC.



D. BORAL
— CAPITAL —